← back to search

Helen Y. Wang

University of Southern California · US
Area of research
Immunology · Molecular Biology
Research interest
Research interests include Immune Cell Function and Interaction, Immunotherapy and Immune Responses, Immune Response and Inflammation, and Inflammasome and immune disorders.
h-index
40
citations
8,239
works
73
NIH funding
primary concept
email

Recent publications

Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Frontiers in Immunology 2022cited by 856position: middledoi
Microbiota regulate innate immune signaling and protective immunity against cancer
Cell Host & Microbe 2021cited by 160position: middledoi
Beclin 2 negatively regulates innate immune signaling and tumor development
Journal of Clinical Investigation 2020cited by 25position: middledoi
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis
Journal of Neuroinflammation 2019cited by 746position: middledoi
Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma
Frontiers in Immunology 2018cited by 218position: middledoi
Assembly of the WHIP-TRIM14-PPP6C Mitochondrial Complex Promotes RIG-I-Mediated Antiviral Signaling
Molecular Cell 2017cited by 89position: middledoi
Immune targets and neoantigens for cancer immunotherapy and precision medicine
Cell Research 2016cited by 231position: lastdoi
Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality
Immunity 2016cited by 120position: middledoi
JMJD3 as an epigenetic regulator in development and disease
The International Journal of Biochemistry & Cell Biology 2015cited by 147position: middledoi
Mechanisms and pathways of innate immune activation and regulation in health and cancer
Human Vaccines & Immunotherapeutics 2014cited by 312position: middledoi
The future potential for cocaine vaccines
Expert Opinion on Biological Therapy 2014cited by 46position: middledoi
Class II Major Histocompatibility Complex Plays an Essential Role in Obesity-Induced Adipose Inflammation
Cell Metabolism 2013cited by 369position: middledoi
Jmjd3 Inhibits Reprogramming by Upregulating Expression of INK4a/Arf and Targeting PHF20 for Ubiquitination
Cell 2013cited by 148position: middledoi
NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4
Nature Immunology 2012cited by 295position: middledoi
TAK1 Negatively Regulates NF-κB and p38 MAP Kinase Activation in Gr-1+CD11b+ Neutrophils
Immunity 2012cited by 159position: middledoi
Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice
Cell Research 2012cited by 137position: middledoi

Grants

SBIR Phase I: 6crickets Automatic Schedule Recommendation
NSF1842790$225,0002019–2020PIRePORTER

Frequent collaborators

Rong‐Fu Wang · University of Southern California16 papers (2012–2022)Changsheng Xing · The University of Texas MD Anderson Cancer Center7 papers (2016–2022)Jun Cui · Xinjiang Medical University5 papers (2012–2017)Peng Tan · Houston Methodist4 papers (2016–2021)Mingjun Wang · Jiamusi University3 papers (2012–2021)Jia Zou · Kunming University of Science and Technology3 papers (2012–2013)Xiao Yu · Huazhong Agricultural University3 papers (2016–2021)Qingyuan Zhu · Center for Life Sciences2 papers (2013–2017)Tianhao Duan · University of Southern California2 papers (2021–2022)Bingnan Yin · Houston Methodist2 papers (2020–2021)Yinyin Li · Qingdao Agricultural University2 papers (2012–2017)Junjun Chu · Anhui University of Traditional Chinese Medicine2 papers (2018–2021)Wenyong Long · Central South University2 papers (2018–2019)Yanzheng Tong · Houston Methodist2 papers (2012–2012)Qingtian Li · Fujian Medical University2 papers (2013–2015)Adebusola Alagbala Ajibade · Houston Methodist2 papers (2012–2021)Qianquan Ma · Peking University2 papers (2018–2019)Motao Zhu · Houston Methodist2 papers (2020–2021)Xin‐zhuan Su · Pennsylvania State University1 papers (2016–2016)Jiahui Zhu · Shandong University1 papers (2021–2021)